The American Cancer Society released updated guidelines on Thursday that represent a significant shift in prostate cancer screening recommendations. The new guidance calls for men aged 50 to 69 at average risk to undergo PSA blood level testing every two years, moving away from the previous approach established in 2010 that left such testing optional and based on individual discretion following a risk discussion with a physician.
For groups facing elevated prostate cancer risk, the recommendations are more aggressive. Black men and those with a family history of prostate cancer are now encouraged to begin yearly PSA-based screening at age 45. The American Cancer Society emphasized that Black men experience disproportionately high mortality rates from prostate cancer, and officials indicated that increased screening may help identify cancers at earlier stages in this population. After age 70, screening decisions shift to an individualized approach, and the guidelines recommend discontinuing screening by age 80 or in men with a life expectancy below 10 years.
The revision reflects recent research demonstrating that PSA screening reduces disease-specific mortality in certain patient populations. PSA testing had fallen out of clinical favor after being removed from guidelines in 2010 due to concerns about low specificity, which led to unnecessary follow-up procedures and overtreatment of slow-growing tumors. To address these concerns, the new guidelines establish a PSA threshold of 3.0 nanograms per milliliter for men aged 45 to 69, and recommend additional steps before biopsy, including confirmatory PSA readings, MRI imaging, and other biomarker testing.
The U.S. Preventive Service Task Force, whose recommendations influence insurance coverage decisions, has not yet adopted similar changes but has announced plans to update its guidelines. The American Cancer Society’s approach attempts to balance early disease detection with reducing unnecessary interventions, emphasizing active surveillance for men diagnosed with slow-growing cancers.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI